Insulin degludec is a long-acting basal insulin used to treat diabetes. It is a component of Rybelsus [1].
What makes insulin degludec long-acting?
Insulin degludec is a human insulin analog designed for prolonged action. It has a specific molecular modification that allows it to form multi-hexamers in the subcutaneous injection site. This depot formation leads to a slow and continuous release of insulin into the bloodstream, providing basal coverage for an extended period [2].
How does insulin degludec compare to other basal insulins?
Compared to other basal insulins like insulin glargine and insulin detemir, insulin degludec offers a more predictable and sustained pharmacokinetic profile [2]. Its ultra-long duration of action allows for greater flexibility in dosing timing, as meals do not need to be precisely timed relative to injections [3].
When does the patent for insulin degludec expire?
The patent expiry for insulin degludec varies by region and specific patent. DrugPatentWatch.com tracks these patents, which are crucial for understanding when generic versions might become available [4]. For example, primary patents for insulin degludec are expected to expire in the coming years, with some exclusivity periods ending around 2026-2030 [4].
Can biosimilars be developed for insulin degludec?
Yes, biosimilars can be developed for insulin degludec once patents and regulatory exclusivity expire. The development process for biosimilars is rigorous, requiring extensive analytical, clinical, and non-clinical data to demonstrate similarity to the reference product [5].
What are the clinical benefits of using insulin degludec?
Clinical trials have shown that insulin degludec effectively lowers blood glucose levels in adults, adolescents, and children aged one year and older with diabetes mellitus. It has demonstrated a similar reduction in HbA1c compared to other basal insulins, with a lower risk of nocturnal hypoglycemia in some studies [2][3].
What are the potential side effects of insulin degludec?
Common side effects associated with insulin degludec include hypoglycemia (low blood sugar), injection site reactions (redness, pain, itching), and lipodystrophy (changes in fat tissue at the injection site). Allergic reactions are also possible [1][3].
How is insulin degludec administered?
Insulin degludec is administered via subcutaneous injection into the abdominal wall, thigh, or upper arm. Dosing frequency is typically once daily, but can be adjusted based on individual needs and physician recommendations [1].
Who manufactures insulin degludec?
Insulin degludec is developed and manufactured by Novo Nordisk [1].
What is the regulatory status of insulin degludec?
Insulin degludec has received regulatory approval in numerous countries, including the United States, European Union, and Japan, for the treatment of diabetes mellitus [1][6].
What are the safety concerns regarding insulin degludec?
The primary safety concern with any insulin therapy, including degludec, is hypoglycemia. Patients and healthcare providers must be vigilant in monitoring blood glucose levels to prevent severe hypoglycemia, which can lead to serious complications [3].
Sources:
[1] https://www.novonordisk.com/
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400754/
[3] https://www.ema.europa.eu/en/medicines/human/EPAR/tresiba
[4] https://drugpatentwatch.com/
[5] https://www.fda.gov/drugs/similarity-and-difference-principles-biologics/biosimilars-and-interchangeable-biologics
[6] https://www.rxlist.com/tresiba-drug.htm